Novavax Stock Brushes Off Vaccine Approval News

The company recently announced upbeat third-quarter financial results

Deputy Editor
Nov 18, 2022 at 10:12 AM
facebook twitter linkedin

Novavax Inc. (NASDAQ:NVAX) just received expanded authorization in Canada for its Covid-19 booster. Regulators in the country have approved the shot for adults in the country that were previously immunized with the company's protein-based vaccine.

NVAX is 0.6% lower despite the news, and was last seen trading at $20.67. The drugmaker recently reported upbeat third-quarter financial results, which helped its shares briefly pop back above the $24 level. Year-over-year, Novavax stock is off by 88.7%. 

Options traders remain firmly settled in the bearish camp. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), NVAX sports a 50-day put/call volume ratio that sits higher than 96% of readings from the past year. 


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners